Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

S2812

Sigma-Aldrich

SNC80

≥98% (HPLC), solid

Synonym(s):

(+)-4-[(αR)-α-((2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-N,N-diethylbenzamide, SNC 80, SNC-80

Sign Into View Organizational & Contract Pricing

Select a Size

5 MG
$766.00
25 MG
$2,380.00

$766.00

Check Cart for Availability
Request a Bulk Order
All Photos(1)

Select a Size

Change View
5 MG
$766.00
25 MG
$2,380.00

About This Item

Empirical Formula (Hill Notation):
C28H39N3O2
CAS Number:
156727-74-1
Molecular Weight:
449.63
MDL number:
MFCD00672673
UNSPSC Code:
12352200
PubChem Substance ID:
24278698
NACRES:
NA.77

$766.00

Check Cart for Availability
Request a Bulk Order

Assay

≥98% (HPLC)

form

solid

color

off-white

solubility

DMSO: soluble

SMILES string

CCN(CC)C(=O)c1ccc(cc1)[C@H](N2C[C@H](C)N(CC=C)C[C@H]2C)c3cccc(OC)c3

InChI

1S/C28H39N3O2/c1-7-17-30-19-22(5)31(20-21(30)4)27(25-11-10-12-26(18-25)33-6)23-13-15-24(16-14-23)28(32)29(8-2)9-3/h7,10-16,18,21-22,27H,1,8-9,17,19-20H2,2-6H3/t21-,22+,27?/m0/s1

InChI key

KQWVAUSXZDRQPZ-QNWUEUMSSA-N

Gene Information

human ... OPRD1(4985)
mouse ... Oprd1(18386)
rat ... Oprd1(24613) , Oprm1(25601)

Application

Rats were administered SNC80 to study the role of nitric oxide synthase in peripheral antinociception mechanism.5

Biochem/physiol Actions

SNC80 is a δ opioid receptor agonist.
SNC80 is a highly selective agonist of δ opioid receptor but also binds to μ-δ opioid receptor heteromers to produce antinociception in mice.2 It also acts as anti-depressant3, elicits dopamine-related behaviors and enhances behavioral responses to psychostimulants.4

Features and Benefits

This compound is featured on the Opioid Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000136411
0000136412
0000134963
0000076505
0000076506

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Matthew D Metcalf et al.
ACS chemical neuroscience, 3(7), 505-509 (2012-08-04)
Coexpressed and colocalized μ- and δ-opioid receptors have been established to exist as heteromers in cultured cells and in vivo. However the biological significance of opioid receptor heteromer activation is less clear. To explore this significance, the efficacy of selective
Richard M van Rijn et al.
The Journal of pharmacology and experimental therapeutics, 335(1), 133-139 (2010-07-08)
Alcoholism and anxiety disorders have a huge impact on society and afflict 17.6 million and 40 million people in the United States, respectively. A strong comorbidity exists between alcoholism and anxiety disorders. Indeed, alcohol withdrawal-induced anxiety is a primary contributing
Paul Chu Sin Chung et al.
Behavioural brain research, 278, 429-434 (2014-12-03)
The delta opioid receptor (DOR) has raised much interest for the development of new therapeutic drugs, particularly to treat patients suffering from mood disorders and chronic pain. Unfortunately, the prototypal DOR agonist SNC80 induces mild epileptic seizures in rodents. Although
Iness Charfi et al.
Cellular and molecular life sciences : CMLS, 71(8), 1529-1546 (2013-09-12)
Signaling bias refers to G protein-coupled receptor ligand ability to preferentially activate one type of signal over another. Bias to evoke signaling as opposed to sequestration has been proposed as a predictor of opioid ligand potential for generating tolerance. Here
Richard M van Rijn et al.
The Journal of pharmacology and experimental therapeutics, 344(1), 179-188 (2012-10-26)
Drugs targeting G-protein-coupled receptors (GPCRs) make up more than 25% of all prescribed medicines. The ability of GPCRs to form heteromers with unique signaling properties suggests an entirely new and unexplored pool of drug targets. However, current in vitro assays
View All Related Papers

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service